PR85560

SAN DIEGO, Sept. 14, 2020 /PRNewswire=KYODO JBN/--

San Diego-based virtual reality (VR) startup Nanome, Inc. has entered into an

agreement with Fujitsu to bring their signature product -- an immersive scientific

design and collaboration platform -- to the Japanese market. The software is already

used by more than 15 of the top US-based biopharmaceutical companies.

Logo - https://mma.prnewswire.com/media/1171590/Nanome_Logo.jpg 

Nanome became the first VR software company to launch an immersive real-time

collaboration platform for scientific discovery in 2015. The software

environment accelerates scientific decision making by allowing users to

visualize, modify, and simulate biological and chemical compounds, facilitating

effective communication of data and integrating with existing computational

chemistry workflows.

"Our software enables the analysis of complicated structures in 3D space," said

Nanome COO Keita Funakawa. "It can help gain insights into data that were not

accessible using 2D tools."

Beginning this month, Fujitsu, a multinational information technology equipment

and services company headquartered in Tokyo, Japan, will sell Nanome software

licenses to Japanese pharmaceutical companies. This places Nanome in one of the

largest markets in the world. The startup hopes to expand the partnership to

address the needs of chemical engineering and materials science companies.

"The number of corporations in Japan using VR software is projected to more

than double by 2025," said Akihiko Harada of Fujitsu. "We were keen to partner

with Nanome to bring this innovative platform to Japan. This partnership is

right in line with our efforts to drive new value from cutting-edge digital

technologies that not only transform the way we work and live, but contribute

to solving global social challenges."

Since the COVID-19 pandemic began late last year, the startup's software has

been used by researchers globally to evaluate the ability of antibody and small

molecule drug candidates to bind the viral proteins. In June, Nanome became the

first US-based company to join European Union government supercomputing efforts

against SARS-CoV-2 by providing virtual reality headsets and Nanome software

access to selected members of the Exscalate4Cov consortium.

"Our partnership with Fujitsu will enable us to provide real-time scientific

collaboration tools to companies at the forefront of the fight against

SARS-CoV-2," said Steve McCloskey, CEO of Nanome. "By making it easy and

intuitive for researchers to evaluate candidate molecules, we hope to help

decrease the time it takes to get an effective drug to market and enable

scientists to stay one step ahead."

MEDIA CONTACT: press@nanome.ai

SOURCE: Nanome, Inc.